Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

Research output: Contribution to journalArticle

Standard

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD : FLAME-based modelling in a Swedish population. / Bjermer, Leif; van Boven, Job F.M.; Costa-Scharplatz, Madlaina; Keininger, Dorothy L.; Gutzwiller, Florian S.; Lisspers, Karin; Mahon, Ronan; Olsson, Petter; Roche, Nicolas.

In: Respiratory Research, Vol. 18, No. 1, 206, 11.12.2017.

Research output: Contribution to journalArticle

Harvard

Bjermer, L, van Boven, JFM, Costa-Scharplatz, M, Keininger, DL, Gutzwiller, FS, Lisspers, K, Mahon, R, Olsson, P & Roche, N 2017, 'Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population', Respiratory Research, vol. 18, no. 1, 206. https://doi.org/10.1186/s12931-017-0688-5

APA

Bjermer, L., van Boven, J. F. M., Costa-Scharplatz, M., Keininger, D. L., Gutzwiller, F. S., Lisspers, K., Mahon, R., Olsson, P., & Roche, N. (2017). Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. Respiratory Research, 18(1), [206]. https://doi.org/10.1186/s12931-017-0688-5

CBE

MLA

Vancouver

Author

Bjermer, Leif ; van Boven, Job F.M. ; Costa-Scharplatz, Madlaina ; Keininger, Dorothy L. ; Gutzwiller, Florian S. ; Lisspers, Karin ; Mahon, Ronan ; Olsson, Petter ; Roche, Nicolas. / Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD : FLAME-based modelling in a Swedish population. In: Respiratory Research. 2017 ; Vol. 18, No. 1.

RIS

TY - JOUR

T1 - Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD

T2 - FLAME-based modelling in a Swedish population

AU - Bjermer, Leif

AU - van Boven, Job F.M.

AU - Costa-Scharplatz, Madlaina

AU - Keininger, Dorothy L.

AU - Gutzwiller, Florian S.

AU - Lisspers, Karin

AU - Mahon, Ronan

AU - Olsson, Petter

AU - Roche, Nicolas

PY - 2017/12/11

Y1 - 2017/12/11

N2 - Background: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. Methods: A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer's perspective and were discounted at 3% annually. Uncertainty in model input values was studied through one-way and probabilistic sensitivity analyses. Subgroup analyses were also performed. Results: IND/GLY was associated with lower costs and better outcomes compared with SFC over all the analysed time horizons. Use of IND/GLY resulted in additional 0.192 LYs and 0.134 QALYs with cost savings of €1211 compared with SFC over lifetime. The net monetary benefit (NMB) was estimated to be €8560 based on a willingness-to-pay threshold of €55,000/QALY. The NMB was higher in the following subgroups: severe (GOLD 3), high risk and more symptoms (GOLD D), females, and current smokers. Conclusion: IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year.

AB - Background: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. Methods: A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer's perspective and were discounted at 3% annually. Uncertainty in model input values was studied through one-way and probabilistic sensitivity analyses. Subgroup analyses were also performed. Results: IND/GLY was associated with lower costs and better outcomes compared with SFC over all the analysed time horizons. Use of IND/GLY resulted in additional 0.192 LYs and 0.134 QALYs with cost savings of €1211 compared with SFC over lifetime. The net monetary benefit (NMB) was estimated to be €8560 based on a willingness-to-pay threshold of €55,000/QALY. The NMB was higher in the following subgroups: severe (GOLD 3), high risk and more symptoms (GOLD D), females, and current smokers. Conclusion: IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year.

KW - Chronic obstructive pulmonary disease

KW - Cost-effective

KW - Exacerbation

KW - Indacaterol/glycopyrronium

UR - http://www.scopus.com/inward/record.url?scp=85037680053&partnerID=8YFLogxK

U2 - 10.1186/s12931-017-0688-5

DO - 10.1186/s12931-017-0688-5

M3 - Article

C2 - 29228950

AN - SCOPUS:85037680053

VL - 18

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 206

ER -